Triple Therapy Rarely Used for Rheumatoid Arthritis Patients

This article originally appeared here.
Share this content:
Triple Therapy Rarely Used for Rheumatoid Arthritis Patients
Triple Therapy Rarely Used for Rheumatoid Arthritis Patients

MONDAY, July 11, 2016 (HealthDay News) -- Patients with rheumatoid arthritis (RA) rarely use triple therapy (methotrexate, sulfasalazine, and hydroxychloroquine), according to a study published in the July issue of Arthritis & Rheumatology.

Jeffrey A. Sparks, M.D., from Brigham and Women's Hospital in Boston, and colleagues used U.S. insurance claims data to examine use of triple therapy among patients with RA in 2009 to 2014. The frequency of intensification to triple therapy or a biologic disease-modifying antirheumatic drug (DMARD) and rates of intensification per six-month time period were evaluated. Factors associated with use of triple therapy were identified.

Data were included for 24,576 patients (78 percent female). The researchers found that treatment was intensified to biologic DMARDs in 11.1 percent of patients and to triple therapy in 0.7 percent of patients during the study period. Across calendar years there was no significant change in triple therapy use. Patients whose treatment was intensified to triple therapy were more likely to receive glucocorticoids and nonsteroidal anti-inflammatory drugs (hazard ratios, 1.91 and 1.48, respectively). Factors significantly associated with triple therapy use included older age, U.S. region (highest odds for use in West and lowest in Northeast), glucocorticoid use, and lower number of outpatient visits.

"Despite reports published during the study period suggesting equivalent efficacy of triple therapy and biologic DMARDs for RA, the use of triple therapy was infrequent and did not increase over time in this large nationwide study," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry, including CVS Health, which provided funding for the study.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

ASH: Synthetic Blood Cell Passes Proof-of-Concept Testing

ASH: Synthetic Blood Cell Passes Proof-of-Concept Testing

Synthetic product made from purified human hemoglobin proteins coated with a synthetic polymer

Fewer School Shootings in States With Tighter Gun Laws

Fewer School Shootings in States With Tighter Gun ...

Study also found that states that spent more money on mental health care, education saw less violence

SABCS: No Survival Benefit Seen for Letrozole Beyond Five Years

SABCS: No Survival Benefit Seen for Letrozole Beyond ...

Study found women who continued with letrozole did experience other benefits, however

is free, fast, and customized just for you!

Already a member?

Sign In Now »